Mereo Under Fire As Shareholder Unrest Erupts
Rubric Demands Board Changes
The UK biotech is developing three key assets - setrusumab, alvelestat and etigilimab - but according to its biggest stockholder, the progress being made is too slow and the share price is too low.
